This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake. Researchers will examine two groups: one just starting AOMs and another that has already achieved significant weight loss and maintained it. By conducting meal challenges at different stages of medication use, the study will assess feasibility of the methods and gather preliminary data to design a larger, future study.
Adult males and females with a BMI of 30-45 kg/m2 (early group), or a BMI of 30-45 kg/m2 prior to weight loss achieved through medication (late group)
Age, 25-60 years old
Passing medical and physical screening, and analysis of blood and urine screening samples
Anticipated to start or are already prescribed AOMs (semaglutide or tirzepatide)
Diagnosed with type 1 or 2 diabetes
Smoker
Previous surgical treatment or device-based therapy for obesity
Chronic or acute pancreatitis